| Amanda Zelinski, | |
|
2401 S 31st St, Temple, TX 76508-0001 | |
| (254) 724-2111 | |
| Not Available |
| Full Name | Amanda Zelinski |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 10 Years |
| Location | 2401 S 31st St, Temple, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013328111 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | BP10050372 (Texas) | Secondary |
| 207P00000X | Emergency Medicine | Q6134 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baylor Scott & White Medical Center Hillcrest | Waco, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Century Integrated Partners, Inc | 6406151703 | 232 |
News Archive
Cepheid today announced it has received clearance from the U.S. Food & Drug Administration to market Xpert Norovirus, a qualitative in vitro diagnostic test for expeditious identification and differentiation of Noroviruses genogroup I (GI) and genogroup II (GII).
AMRI has commenced enrollment for a Phase I study of ALB-127158(a), a novel MCH1 receptor antagonist offering a potential new approach for the treatment of obesity. The announcement was made yesterday during a presentation by AMRI's Dr. Peter Guzzo, director, discovery research and development, at the 6th Obesity and Diabetes Drug Development Summit in Arlington, VA. Preclinical data were also reported.
Clinical features that can appear many years ahead of a psychiatric diagnosis may help doctors to predict whether patients will develop bipolar disorder or unipolar depression, say researchers.
In vitro studies of the cellular effects of modeled osteopathic manipulative therapy (OMT) provide proof of concept for the manual techniques practiced by doctors of osteopathic medicine (DOs), according to researchers from the University of Arizona College of Medicine - Phoenix.
› Verified 4 days ago
| Entity Name | Century Integrated Partners, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447615711 PECOS PAC ID: 6406151703 Enrollment ID: O20160224002152 |
News Archive
Cepheid today announced it has received clearance from the U.S. Food & Drug Administration to market Xpert Norovirus, a qualitative in vitro diagnostic test for expeditious identification and differentiation of Noroviruses genogroup I (GI) and genogroup II (GII).
AMRI has commenced enrollment for a Phase I study of ALB-127158(a), a novel MCH1 receptor antagonist offering a potential new approach for the treatment of obesity. The announcement was made yesterday during a presentation by AMRI's Dr. Peter Guzzo, director, discovery research and development, at the 6th Obesity and Diabetes Drug Development Summit in Arlington, VA. Preclinical data were also reported.
Clinical features that can appear many years ahead of a psychiatric diagnosis may help doctors to predict whether patients will develop bipolar disorder or unipolar depression, say researchers.
In vitro studies of the cellular effects of modeled osteopathic manipulative therapy (OMT) provide proof of concept for the manual techniques practiced by doctors of osteopathic medicine (DOs), according to researchers from the University of Arizona College of Medicine - Phoenix.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amanda Zelinski, Po Box 844658, Dallas, TX 75284-4658 Ph: (254) 724-8800 | Amanda Zelinski, 2401 S 31st St, Temple, TX 76508-0001 Ph: (254) 724-2111 |
News Archive
Cepheid today announced it has received clearance from the U.S. Food & Drug Administration to market Xpert Norovirus, a qualitative in vitro diagnostic test for expeditious identification and differentiation of Noroviruses genogroup I (GI) and genogroup II (GII).
AMRI has commenced enrollment for a Phase I study of ALB-127158(a), a novel MCH1 receptor antagonist offering a potential new approach for the treatment of obesity. The announcement was made yesterday during a presentation by AMRI's Dr. Peter Guzzo, director, discovery research and development, at the 6th Obesity and Diabetes Drug Development Summit in Arlington, VA. Preclinical data were also reported.
Clinical features that can appear many years ahead of a psychiatric diagnosis may help doctors to predict whether patients will develop bipolar disorder or unipolar depression, say researchers.
In vitro studies of the cellular effects of modeled osteopathic manipulative therapy (OMT) provide proof of concept for the manual techniques practiced by doctors of osteopathic medicine (DOs), according to researchers from the University of Arizona College of Medicine - Phoenix.
› Verified 4 days ago
Lucas Mark Alexander, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: Baylor Scott & White Medical Center-temple, 2401 S 31st, Ms-11-ag062, Temple, TX 76508 Phone: 254-724-5815 | |
Victoria Schneider Klovenski, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111 | |
Van Steven Mask, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1901 Sw H K Dodgen Loop, Temple, TX 76502 Phone: 254-771-8600 | |
Dr. Jon E. Jaffe, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111 | |
Dr. Robert D. Greenberg, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111 | |
Dr. Caleb Cadis, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: Dept Of Emergency Medicine 2401 S 31st St, Ms-11-ag062, Temple, TX 76508 Phone: 254-724-5815 |